Atterx Biotherapeutics
PrivateLast Round
Convertible Debt
Mar 31, 2025
Total Funding Raised
$12.98M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Atterx Biotherapeutics is a biotechnology company that develops novel therapies to combat multi-drug resistant bacterial infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atterx Biotherapeutics Comparables
Compare Atterx Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VenatoRx Pharmaceuticals | 79% | |
| Fimbrion Therapeutics | 78% | |
| Omnix Medical Ltd. | 77% |
Atterx Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Mar 31, 2025 | ||||
| Early Funding | Jan 13, 2023 | ||||
| Series C Extension | Jun 1, 2022 | ||||
| VC Round | Apr 25, 2016 | ||||
| Series B | May 14, 2010 | ||||
Grant | Oct 24, 2008 |
Atterx Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boomerang Catapult | Series C Extension, Early Funding |
| Northern Michigan Angels | Early Funding |
| U.S. Department of War | Grant |
| Michigan Rise | Early Funding |
| Michigan Strategic Fund | Convertible Debt, Early Funding |
| Wisconsin Investment Partners | Series B, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Monthly visitors grew 39% MoM, reaching 1.2K.
- May 21, 2026
Monthly visitors increased 45% MoM.
Atterx Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Atterx Biotherapeutics's valuation, stock price, and market status.
Is Atterx Biotherapeutics a public or private company?
Atterx Biotherapeutics is a private company.
What is the current stock price of Atterx Biotherapeutics?
Atterx Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Atterx Biotherapeutics worth (valuation)?
Valuation information for Atterx Biotherapeutics is not publicly available.
Can I buy Atterx Biotherapeutics stock?
Atterx Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Atterx Biotherapeutics's last funding round?
Atterx Biotherapeutics's most recent funding round was Series C Extension on January 17, 2023.
Who are the main investors in Atterx Biotherapeutics?
Key investors in Atterx Biotherapeutics include Michigan Rise.
Will Atterx Biotherapeutics IPO soon?
No public IPO plans have been announced for Atterx Biotherapeutics.
How can I track Atterx Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Atterx Biotherapeutics's secondary market activity and sign up for updates.